UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

British journal of haematology, 2007-02, Vol.136 (3), p.439-447

2007

Volltextzugriff (PDF)

Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma

Hematological oncology, 2024-01, Vol.42 (1), p.e3227-n/a

2024

Volltextzugriff (PDF)

ABCL-119 Tumor CD20 Loss and Poor Outcome in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S457-S457

2024

Volltextzugriff (PDF)

Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects

Critical reviews in oncology/hematology, 2024-07, Vol.199, p.104390, Article 104390

2024

Volltextzugriff (PDF)

Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy

Frontiers in oncology, 2024-08, Vol.14, p.1425506

2024

Volltextzugriff (PDF)

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma

Best practice & research. Clinical haematology, 2023-03, Vol.36 (1), p.101442-101442, Article 101442

2023

Volltextzugriff (PDF)

Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

World journal of clinical cases, 2021-04, Vol.9 (10), p.2394-2399

2021

Volltextzugriff (PDF)

Lenalidomide in relapsed refractory non-Hodgkin's lymphoma: An Indian perspective

Journal of cancer research and therapeutics, 2015-10, Vol.11 (4), p.857-861

2015

Volltextzugriff (PDF)

Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy

Frontiers of medicine, 2020-12, Vol.14 (6), p.786-791

2020

Volltextzugriff (PDF)

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group

Cancers, 2022-03, Vol.14 (7), p.1761

2022

Volltextzugriff (PDF)

Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

Expert opinion on pharmacotherapy, 2010-08, Vol.11 (11), p.1915-1923

2010

Volltextzugriff (PDF)

ABCL-255: Prognostic Significance of PET CT in Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin Lymphoma Before Transplantation of Autologous Hematopoietic Progenitors: Experience of a Public Hospital

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S269-S269

2020

Volltextzugriff (PDF)

Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma

Gan to kagaku ryoho, 2015-01, Vol.42 (1), p.51

2015

Volltextzugriff (PDF)

Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma

European journal of haematology, 1995-10, Vol.55 (4), p.223-227

1995

Volltextzugriff (PDF)

A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram

Cancer Immunology, Immunotherapy, 2024-01, Vol.73 (2), p.33-33, Article 33

2024

Volltextzugriff (PDF)

The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymphoma

Cancer chemotherapy and pharmacology, 2016-10, Vol.78 (4), p.801-808

2016

Volltextzugriff (PDF)

Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin’s lymphoma patients in England

Leukemia research, 2023-04, Vol.127, p.107042-107042, Article 107042

2023

Volltextzugriff (PDF)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Annals of oncology, 2018-09, Vol.29 (9), p.1932-1938

2018

Volltextzugriff (PDF)

Early lymphocyte collection for anti‐CD19 CART production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma

British journal of haematology, 2023-07, Vol.202 (1), p.74-85

2023

Volltextzugriff (PDF)

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non‐Hodgkin lymphoma

British journal of haematology, 2019-03, Vol.184 (5), p.744-752

2019

Volltextzugriff (PDF)

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience

Cancers, 2021-09, Vol.13 (19), p.4789

2021

Volltextzugriff (PDF)

Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning

Leukemia & lymphoma, 2016-11, Vol.57 (11), p.2499-2509

2016

Volltextzugriff (PDF)

Early experience using salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

British journal of haematology, 2020-07, Vol.190 (1), p.45-51

2020

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(132)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(116)
Science & Technology
(116)
Humans
(89)
Oncology
(76)
Hematology
(63)
Lymphoma
(50)
Adult
(43)
Lymphoma, Non-Hodgkin - Drug Therapy
(42)
Male
(42)
Middle Aged
(42)
Female
(41)
Aged
(39)
Chemotherapy
(34)
Relapsed
(34)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(33)
Patients
(33)
Refractory
(33)
Non-Hodgkin's Lymphomas
(29)
Recurrence
(27)
Treatment Outcome
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma

ABCL-119 Tumor CD20 Loss and Poor Outcome in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects

Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy

Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma

Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

Lenalidomide in relapsed refractory non-Hodgkin's lymphoma: An Indian perspective

Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group

Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

ABCL-255: Prognostic Significance of PET CT in Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin Lymphoma Before Transplantation of Autologous Hematopoietic Progenitors: Experience of a Public Hospital

Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma

Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma

A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram

The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymphoma

Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin’s lymphoma patients in England

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Early lymphocyte collection for anti‐CD19 CART production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non‐Hodgkin lymphoma

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience

Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning

Early experience using salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

Suchergebnisse filtern